Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a ...

Boston Scientific posted stellar third-quarter results ... Quarterly operational revenue growth of 20% exceeded our expectations, with Farapulse driving the electrophysiology, or EP, category ...

Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...

The FDA is elevating a recall from Boston Scientific covering its cryoablation balloon catheters for the treatment of atrial ...

Devices already in inventory can be used with the updated instructions by doctors. Patients already treated don’t need to do ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...

Dr. Robert Ward prepares part of the FARAPULSE Pulsed Field Ablation System for a pulsed field ablation procedure to treat a patient with atrial fibrillation at Mayo Clinic Hospital, Saint Marys ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...

The update followed a higher than expected number of reports of esophageal injury after catheter ablation procedures for ...

Boston Scientific updates Polarx catheter guidelines due to atrio-esophageal fistula risks, highlighting safer usage practices after FDA approval.

Valued at a market cap of $133.6 billion, Boston Scientific Corporation (BSX ... strategic acquisitions like Farapulse, its category leadership strategy, and robust operational execution ...

Four PFA systems have launched in the U.S. in the past year: Medtronic’s PulseSelect and Affera Sphere-9, Boston Scientific’s Farapulse and J&J's Varipulse. The Citi survey polled 36 ...